109229-22-3

Basic information

• Product Name: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one
• Synonyms: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one;6-Benzyl-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one;3-d]pyriMidin-4(3H)-one;6-benzyl-5;6-benzyl-3H,4H,5H,6H,7H,8H-pyrido[4,3-d]pyriMidin-4-one;6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyriMidin-4-one;Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyriMidin-4(3H)-one;6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)
• CAS NO: 109229-22-3
• Molecular Formula: C₁₄H₁₅N₃O
• Molecular Weight: 241.29
• Product Categories: CHIRAL CHEMICALS
• Mol File: 109229-22-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 165-166.5 °C(Solv: acetone (67-64-1))
• Boiling Point: 406.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.27 g/cm³
• Refractive Index: 1.662
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.65±0.20(Predicted)
• CAS DataBase Reference: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(109229-22-3)
• EPA Substance Registry System: 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(109229-22-3)

Safety Data

• Hazardous Substances Data: 109229-22-3(Hazardous Substances Data)

Usage

Description

6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one is a chemical compound belonging to the class of tetrahydropyrimidines. It is characterized by its unique molecular structure, which features a benzyl group attached to the 6th position and a pyrimidine ring fused with a pyridine ring. 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one has garnered interest in the field of medicinal chemistry due to its potential applications in drug discovery and optimization.

Uses

Used in Pharmaceutical Industry:
6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one is used as a key intermediate in the discovery and optimization of quinazolinones. These quinazolinones are being investigated as new P2X3 receptor antagonists, which have potential therapeutic applications in treating various conditions such as chronic cough, pain, and inflammatory disorders.
The compound's unique structure allows for the development of novel P2X3 receptor antagonists with improved potency, selectivity, and pharmacokinetic properties. By targeting the P2X3 receptor, these quinazolinones can modulate the body's response to pain and inflammation, offering a promising avenue for the development of new therapeutic agents.

InChI:InChI=1/C14H15N3O/c18-14-12-9-17(7-6-13(12)15-10-16-14)8-11-4-2-1-3-5-11/h1-5,10H,6-9H2,(H,15,16,18)

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 6313-33-3 formamidine hydrochloride 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 159660-85-2 1-benzyl-4-aminotetrahydropyridine-3-carboxylic acid methyl ester 
• 463-52-5 formamidine 
• 3473-63-0 formamidine acetic acid 
• 67848-59-3 4-piperidone-3-carboxylic acid ethyl ester 
• 618-32-6 Benzoyl bromide 

Downstream Products

• 1430100-84-7 6-[3-(1,3-benzothiazol-2-yl)propanoyl]-4-(4-fluorobenzyl)-5,6,7,8-tetrahydropyrido-[4,3-d]pyrimidine 
• 1430101-38-4 6-benzyl-4-bromo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1430101-39-5 6-benzyl-4-(4-fluorobenzyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1056934-87-2 tert-butyl 4-chloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1071436-29-7 (S)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-(4-trifluoromethyl-phenyl)-ethanol 
• 1071436-10-6 (R)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-phenyl-ethanol 
• 1071436-17-3 [(R)-1-(4-chloro-phenyl)-ethyl]-[6-(5-chloro-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine 
• 1071436-05-9 [6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-((R)-1-p-tolyl-ethyl)-amine 
• 1071436-20-8 (R)-N-(1-(4-chlorophenyl)ethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1071436-19-5 (R)-6-benzyl-N-(1-(4-chlorophenyl)ethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 944902-70-9 4-methoxy-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine 
• 1071435-57-8 6-benzyl-4-methoxy-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1332455-21-6 tert-butyl 2-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.5]nonane-7-carboxylate 
• 1332455-30-7 ethyl 1-(6-(4-chlorophenylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)piperidine-4-carboxylate 

Relevant articles and documents

New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones

Numerous potent P2X3 antagonists have been discovered and the therapeutic potential of P2X3 antagonism already comprises proof-of-concept data obtained in clinical trials with the most advanced compound. We have lately reported the discovery and optimization of thia-triaza-tricycle compounds with potent P2X3 antagonistic properties. This Letter describes the SAR of a back-up series containing a 4-oxo-quinazoline central ring. The discovery of the highly potent compounds 51 is presented.

New tetrahydropyrido pyrimidinecarboxylic compound or salt thereof

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL IN THERAPY

The invention provides compounds of formula (I), wherein one of X, Y and Z represents N and the other two represent CH, or X=Y-Z represents N=CH-N; W represents a CI-6 alkylene group which may be straight or branched; R1 represents H, phenyl, naphthyl, heteroaryl1, heterocyclyl1 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl', heterocyclyl1 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and each heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a benzene ring; m is 1 or 2; n is 0, 1 or 2; A is C=O or SO2; V represents a bond or C1-8 alkylene which may be straight or branched; R2 represents H, -S-(C1-6 alkyl), -SO2N(C1-6 alkyl)2, -CO2-(C1-6 alkyl), - NHCOCH2-phenyl, -OCH2- phenyl, -S02-phenyl, -NR3R4, phenyl, naphthyl, heteroaryl2, heterocyclyl2, -CO-heterocyclyl2 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and wherein each heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a benzene ring; and pharmaceutically acceptable salts and solvates thereof. The compounds are useful as pharmaceuticals, particularly in the treatment of fibrotic diseases, cancer and pain.